

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Anti-WWTR1 polyclonal antibody

RRID:AB_1080602

Type: Antibody

Proper Citation

Atlas Antibodies Cat# HPA007415, RRID:AB_1080602

Antibody Information

URL: http://antibodyregistry.org/AB_1080602

Proper Citation: Atlas Antibodies Cat# HPA007415, RRID:AB_1080602

Target Antigen: WWTR1

Host Organism: rabbit

Clonality: polyclonal

Comments: Originating manufacturer of this product. Applications: ICC-IF, IHC, WB. Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues. Genetic validation in WB by siRNA knockdown. Immunogen: Recombinant Protein Epitope Signature Tag (PrEST).

Antibody Name: Anti-WWTR1 polyclonal antibody

Description: This polyclonal targets WWTR1

Target Organism: mouse, human

Antibody ID: AB_1080602

Vendor: Atlas Antibodies

Catalog Number: HPA007415

Record Creation Time: 20250820T005817+0000

Record Last Update: 20250820T094116+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas <https://www.proteinatlas.org/search/HPA007415>

No alerts have been found for Anti-WWTR1 polyclonal antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. Cancer research, 86(12), 2860.

Gautier M, et al. (2026) A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity. Cell reports, 45(5), 117351.

Seol T, et al. (2026) YAP/TAZ-VGLL3 governs adipocyte fate via epigenetic reprogramming of PPAR?? and its target enhancers. Science advances, 12(3), eaea7235.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. Molecular cell.

Corujo-Simon E, et al. (2024) Human trophectoderm becomes multi-layered by internalization at the polar region. Developmental cell, 59(18), 2497.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Qi S, et al. (2023) Two Hippo signaling modules orchestrate liver size and tumorigenesis. The EMBO journal, e112126.

Warren R, et al. (2023) Hippo signaling impairs alveolar epithelial regeneration in pulmonary fibrosis. eLife, 12.

Gu Y, et al. (2022) Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers. Cell reports, 40(9), 111296.

Qi S, et al. (2022) WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Molecular cell, 82(10), 1850.

Chen N, et al. (2022) YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4. Cell reports, 39(11), 110970.

Vigneswaran K, et al. (2021) YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(5), 1553.

Hicks-Berthet J, et al. (2021) Yap/Taz inhibit goblet cell fate to maintain lung epithelial homeostasis. *Cell reports*, 36(2), 109347.

Mygland L, et al. (2021) Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines. *iScience*, 24(7), 102807.

Barthet VJA, et al. (2021) Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver. *Science advances*, 7(23).

Lodge EJ, et al. (2019) Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade. *eLife*, 8.

LeBlanc L, et al. (2018) Yap1 safeguards mouse embryonic stem cells from excessive apoptosis during differentiation. *eLife*, 7.

Hu JK, et al. (2017) An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice. *Cell stem cell*, 21(1), 91.

Levasseur A, et al. (2017) Targeted Disruption of YAP and TAZ Impairs the Maintenance of the Adrenal Cortex. *Endocrinology*, 158(11), 3738.

Diamantopoulou Z, et al. (2017) TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. *Cancer cell*, 31(5), 621.